Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused by several distinct families of viruses. In general, the term "viral hemorrhagic fever" is used to describe a severe multisystem syndrome (multisystem in that multiple organ systems in the body are affected). Characteristically, the overall vascular system is damaged, and the body's ability to regulate itself is impaired. These symptoms are often accompanied by hemorrhage (bleeding); however, the bleeding is itself rarely life-threatening. While some types of hemorrhagic fever viruses can cause relatively mild illnesses, many of these viruses cause severe, life-threatening disease.
After smouldering in the Democratic Republic of Congo (DRC) for almost a year, killing near 1,000 people, the deadly Ebola virus crossed the border to Uganda in June 2019. This virus causes sudden high fever and sore throat, with severe weakness and muscle pain.
Dengue fever stopped spreading in an Australian city, called Townsville, after an army of mosquitoes infected with the Wolbachia bacterium was released on it.
The U.S. Food and Drug Administration announced today the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people ages 9 through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas.
The University of Texas Medical Branch at Galveston, Profectus Biosciences, Vanderbilt University Medical Center, Mapp Biopharmaceutical and Genevant Sciences Corp. have been awarded up to $35 million to advance the development of rapid-acting vaccines and broad-spectrum treatments of the highly-lethal hemorrhagic fever viruses Ebola and Marburg.
The National Institute of Allergy and Infectious Diseases has awarded an international consortium led by Albert Einstein College of Medicine, part of Montefiore, a five-year, $22 million grant to develop antibody-based therapies against four highly lethal viruses for which there are no approved vaccines or treatments.
About 40 percent of the global population is at risk for contracting dengue - the most important mosquito-borne viral infection and a close "cousin" of the Zika virus - and yet, no effective treatment or safe licensed vaccine exists.
Staten Island residents have another reason to apply insect repellent and obsessively check for ticks this spring and summer: the population of a new, potentially dangerous invasive pest known as the Asian longhorned tick has grown dramatically across the borough, according to Columbia University researchers.
It was recently reported that the number of Ebola cases in the Democratic Republic of Congo has surpassed 1,000, making it the second-worst outbreak in history after the 2014 outbreak in West Africa in which 29,000 people were infected and more than 11,000 died.
Dr Paulo Rocha from the University of Bath's Department of Electronic & Electrical Engineering is developing a low-cost integrative sensing tool for early detection of Dengue virus, using a novel platform containing electrical sensors to investigate the behavior of human cells infected with Dengue virus.
Dubbed ‘Disease X’, scientists believe a future epidemic of the influenza virus could cause millions of deaths worldwide.
A research team from Tübingen and Göttingen has described in the renowned journal Cell Reports a new mechanism how the Ebola virus escapes the immune system.
A Phase 1 clinical trial of investigational vaccines intended to protect against Zaire ebolavirus (Ebola) is underway at Cincinnati Children's Hospital Medical Center in the United States. The study is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
A team of researchers have discovered the interaction between an Ebola virus protein and a protein in human cells that may be an important key to unlocking the pathway of replication of the killer disease in human hosts.
Two groundbreaking discoveries by USC researchers could lead to medications and a vaccine to treat or prevent a hemorrhagic fever transmitted by a new tick species before it spreads across the United States.
A new study has tried to assess the genetic variants among mosquitoes that make them more susceptible to spreading deadly viral diseases such as dengue, yellow fever, Zika and chikungunya and more resistant to insecticides that are used to kill them.
The Walter Reed Army Institute of Research this week administered the first vaccine in a Phase 1 clinical trial to evaluate the safety and immunogenicity of a Marburg vaccine candidate in healthy adult volunteers.
Lassa fever belongs to the same class of hemorrhagic fevers as Ebola. Like Ebola, it has been a major health threat in Western Africa, infecting 100,000-300,000 people and killing 5,000 per year.
A synthetic DNA vaccine has been shown to provide complete and enduring protection from Ebola virus in preclinical studies.
African swine fever virus threatens to devastate the swine industry and is positioned to spread throughout Asia. The virus has spread throughout the Caucuses region of Eastern Europe and was reported in China in August. It recently was detected in wild boar in Belgium.
Scientists hope that a new approach to vaccine development, combined with improved surveillance of potential future threats of outbreak, could help to massively reduce the impact of deadly diseases such as Ebola, Marburg and Lassa fever.